BioNTech (NASDAQ:BNTX) Price Target Cut to $138.00 by Analysts at HC Wainwright

BioNTech (NASDAQ:BNTX - Get Free Report) had its target price dropped by HC Wainwright from $145.00 to $138.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's price objective suggests a potential upside of 32.18% from the company's previous close. HC Wainwright also issued estimates for BioNTech's Q4 2025 earnings at $0.51 EPS, Q1 2026 earnings at ($2.23) EPS, Q2 2026 earnings at ($2.25) EPS, Q3 2026 earnings at ($0.72) EPS, Q4 2026 earnings at $0.88 EPS and FY2026 earnings at ($5.35) EPS.

Several other research analysts have also weighed in on BNTX. Wall Street Zen upgraded shares of BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. BMO Capital Markets increased their price objective on shares of BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Citigroup reiterated a "buy" rating and set a $140.00 price objective (down from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Morgan Stanley cut their price objective on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. cut their price objective on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, BioNTech has a consensus rating of "Moderate Buy" and an average target price of $137.86.

BioNTech Trading Down 0.5%

Shares of BNTX stock traded down $0.57 during trading hours on Monday, hitting $104.40. 894,938 shares of the company were exchanged, compared to its average volume of 949,716. The firm has a market cap of $25.10 billion, a PE ratio of -30.71 and a beta of 1.29. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The company has a quick ratio of 10.02, a current ratio of 10.18 and a debt-to-equity ratio of 0.01. The firm has a fifty day moving average of $101.79 and a 200 day moving average of $107.84.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. FMR LLC grew its position in shares of BioNTech by 22.2% during the fourth quarter. FMR LLC now owns 7,701,476 shares of the company's stock worth $877,583,000 after buying an additional 1,401,547 shares in the last quarter. Flossbach Von Storch SE boosted its holdings in BioNTech by 1.1% in the fourth quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company's stock worth $502,160,000 after purchasing an additional 47,236 shares during the period. Capital International Investors boosted its holdings in BioNTech by 38.6% in the fourth quarter. Capital International Investors now owns 1,415,566 shares of the company's stock worth $161,304,000 after purchasing an additional 394,434 shares during the period. BNP Paribas Financial Markets boosted its holdings in BioNTech by 94.6% in the first quarter. BNP Paribas Financial Markets now owns 1,195,470 shares of the company's stock worth $108,859,000 after purchasing an additional 581,173 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in BioNTech by 18,892.9% in the first quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock worth $63,593,000 after purchasing an additional 694,691 shares during the period. 15.52% of the stock is owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.